-
Posted by
Two Blokes Apr 29 -
Filed in
Stock
-
0 views
Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance from its oncology portfolio. The Anglo-Swedish drugmaker reiterated its guidance for the full year, forecasting high single-digit percentage growth in total revenue and a low double-digit percentage rise in core earnings per share at constant exchange rates.
